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Adverse drug effects Summary Environmental scientists are now raising great concern on the impact of drugs on the environment and microbiologists are concerned about increasing antibiotic resistance due to irrational usage. However, a focus on the impact by the use of antibiotics (irrational/prescribed) to the environment at therapeutic doses has not been instituted. Even the World Health Organization (WHO) defined ''Pharmacovigilance'' activities as the monitoring, detection, assessment, understanding and prevention of any adverse reactions to drugs at therapeutic concentration on animals and humans. Nevertheless, there is little attention being given to identifying the adverse effects (ADEs) of antimicrobial agents on the environment (given at therapeutic doses). This issue has been highlighted in the present commentary and a new domain, ''Pharmaco-EcoMicrobiology'', has been proposed which should deal with and monitor such adverse effects. The term ''Pharmaco-EcoMicrobiology'' has been proposed to define the interplay between antimicrobial pharmacological agents and animate microbial ecology. This new domain, ''Pharmaco-EcoMicrobiology'', has been derived by the aggregation of three important branches of science (pharmacology + ecology + microbiology) and would be responsible for studying the ADEs due to antimicrobial drugs excreted in environment. In this article, We propose the term ''PharmacoEcoMicrobiology'' to define the interplay between pharmacological antimicrobial agent and animate microbial ecology. A detailed algorithm describing the components of this newer domain and the adverse drug effects (ADEs) occurring and to be monitored under this domain is shown in Fig. 1 . In brief, this proposed domain includes medical and veterinary components through which the metabolized and non-metabolized antimicrobial drugs in human and animal guts, as well as those excreted in the environment, give rise to the development of antibiotic resistance in bacteria due to the selection pressure. These multi-drug resistant (MDR) organisms are then responsible for giving rise to MDR infections.
To review possible sources of antibiotics in the environment, including those mentioned above; these could be as follows:
(a) Sewage: The antibiotics that we take in are not all processed by our bodies. Clearly, the unprocessed drug will pass into the environment along with feces and urine and ultimately reside in our wastewater treatment plants. Not only unprocessed drugs, but also the metabolites with active components excreted through the same routes. According to the World Health Organization (WHO), ''Pharmacovigilance'' activities are done to monitor detection, assessment, understanding and prevention of any obnoxious adverse reactions to drugs at therapeutic concentration on animals and humans. However, in recent years, environmental scientists have raised a great concern on the impacts of drugs on the environment and surround-ing [1] . To summarize a few noteworthy hazardous impacts reported previously, first the detection of drugs in sewage at Big Blue River sewage treatment plant at Kansas City, Missouri [2] , a vulture's death after consumption of animal carcasses treated with diclofenac sodium [3, 4] , and feminization of male fish by ethinyl estradiol [5] . There are also other reports on disturbed environmental fauna due to drugs eliminated in environmental surroundings. In recent years, microbiologists have raised great concerns about increasing antibiotic resistance [6] [7] [8] [9] focusing much on irrational use. However, a focus on the impact to the environment by the use of irrationally prescribed antibiotics at therapeutic doses has not been instituted. Nevertheless, there should be concern to find the adverse effects of antimicrobial drugs on the environment given at therapeutic doses. Therefore, it is interesting to note that despite selective pressure and increasing antibiotic resistance in microorganism nobody has addressed for the vigilance of ADEs due to antimicrobials prescribed at therapeutic doses to human beings and animals. One could argue that the effect of antimicrobial agents and their effect on microorganisms causing direct or indirect damage to humans or animals is a component of environmental microbiology. It should therefore be emphasized here that ''Environmental Microbiology'' only deals with the study of microorganisms living in a variety of environments (air, soil, water, etc.) and their pathogenic relationship to other organisms including man, and not with ADEs. Similarly it is true for ''Ecopharmacology'' (Ecosystem + Pharmacology) which describes entry of chemicals or drugs into the environment through any route disturbing the balance of ecology as a consequence. If these drugs enter through living beings via elimination subsequent to pharmacotherapy, logically it should be a specific domain of ''pharmacology'' and not of environmental studies. And when it disturbs the ecosystem, especially in relation to microorganisms, it also includes components of ''ecology'' and ''microbiology''. Hence, we propose this newer domain of science as ''Pharmaco-EcoMicrobiology'' (pharmacology + ecosystem + microbiology), which should govern the aspects discussed above including the ADEs on microorganisms due to antimicrobial drugs excreted in the environment at therapeutic doses.
These suggestions are not clearly defined in the definition of ''Environmental Microbiology'' and ''Ecopharmacology''. Moreover, there is lack of such a term in the existing literature that takes into account medical, veterinary, and environmental aspects of very common practices of use, abuse and overuse of antimicrobial agents. Therefore, we suggest that the adverse effects due to the discharge of antimicrobial agents in environment by above-mentioned routes (c-e) could be component of environmental microbiology, however, the antimicrobial agents excreted in the environment after consumption at therapeutic doses could be a component of ''Pharmaco-EcoMicrobiology'' and therefore should be included as a new component of pharmacovigilance or a component bridging pharmacovigilance to ecology and environmental microbiology.
